Just 2 doses of a vaccine against human papillomavirus (HPV) strains that can cause cervical cancer may provide protection similar to that of the recommended 3-dose regimen, suggest results of a clinical trial in Costa Rica.
The investigators analyzed data from 5967 women who received 3 doses of Cervarix (which protects against HPV types 16 and 18) or a control vaccine, 802 who received 2 doses of either vaccine, and 384 women who received only 1 dose of either vaccine (Kreimer AR, et al. J Natl Cancer Inst. 2011;103:1-8). When they compared the 4-year incidence of HPV 16 or 18 infections in each group, they found similar levels of protection against infection with HPV 16 or 18 in the women receiving either 2 (84.1% efficacy) or 3 (80.9% efficacy) doses of the HPV vaccine. No infections were detected among women in the 1-dose group, but the authors acknowledge that this may be a consequence of the small number of women in this group.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.